AU Patent

AU2003258433A1 — Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma

Assigned to Merck Canada Inc · Expires 2004-03-19 · 22y expired

What this patent protects

Patent listed against Lumigan.

Drugs covered by this patent

Patent Metadata

Patent number
AU2003258433A1
Jurisdiction
AU
Classification
—
Expires
2004-03-19
Drug substance claim
No
Drug product claim
No
Assignee
Merck Canada Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.